---
title: "Fate Therapeutics, Inc. (FATE.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/FATE.US.md"
symbol: "FATE.US"
name: "Fate Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-04-16T07:49:09.740Z"
locales:
  - [en](https://longbridge.com/en/quote/FATE.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/FATE.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/FATE.US.md)
---

# Fate Therapeutics, Inc. (FATE.US)

## Company Overview

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.fatetherapeutics.com](https://www.fatetherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-16T04:30:17.000Z

**Overall: D (0.75)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 283 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -51.24% |  |
| Net Profit YoY | 26.82% |  |
| P/B Ratio | 0.72 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 149979862.11 |  |
| Revenue | 6646000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -51.84% | E |
| Profit Margin | -2051.08% | E |
| Gross Margin | -1282.77% | E |
| Revenue YoY | -51.24% | E |
| Net Profit YoY | 26.82% | B |
| Total Assets YoY | -27.63% | E |
| Net Assets YoY | -35.00% | E |
| Cash Flow Margin | 77.82% | C |
| OCF YoY | -51.24% | E |
| Turnover | 0.02 | E |
| Gearing Ratio | 35.04% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Fate Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-51.24%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "26.82%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.72",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "149979862.11",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "6646000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-51.84%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-2051.08%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-1282.77%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-51.24%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "26.82%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-27.63%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-35.00%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "77.82%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-51.24%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.02",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "35.04%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.10 | 197/393 | - | - | - |
| PB | 0.72 | 59/393 | 0.64 | 0.51 | 0.45 |
| PS (TTM) | 22.57 | 206/393 | 20.12 | 15.94 | 10.40 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 04 | CapForce Inc. (CFOR.US) | B | A | A | A | C | A |
| 05 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-19T04:00:00.000Z

Total Analysts: **12**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 42% |
| Overweight | 1 | 8% |
| Hold | 6 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.29 |
| Highest Target | 8.00 |
| Lowest Target | 2.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/FATE.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/FATE.US/norm.md)
- [Related News](https://longbridge.com/en/quote/FATE.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/FATE.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**